Efficiency of AUY922 in mice with adult T-cell leukemia/lymphoma

Ishikawa,Chie; Senba,Masachika; Mori,Naoki

doi:10.3892/ol.2016.4624

Efficiency of AUY922 in mice with adult T-cell leukemia/lymphoma

Authors:
- Chie Ishikawa
- Masachika Senba
- Naoki Mori
View Affiliations

Affiliations: Department of Microbiology and Oncology, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa 903‑0215, Japan, Department of Pathology, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852‑8523, Japan
Published online on: May 25, 2016 https://doi.org/10.3892/ol.2016.4624
Pages: 387-392
Copyright: © Ishikawa et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Adult T-cell leukemia/lymphoma (ATLL) is an aggressive malignancy caused by human T-cell leukemia virus type 1 (HTLV-1). ATLL is associated with poor prognosis mainly due to resistance to chemotherapy, which highlights the requirement for alternative therapies. The chaperone heat shock protein (HSP) 90 assist proteins involved in the onset and progression of ATLL. In the present study, the efficacy of a second generation HSP90 inhibitor termed AUY922 was investigated in ATLL. In vitro, AUY922 induced marked inhibition of cell viability in the HTLV‑1‑infected T‑cell lines HUT‑102 and MT‑4. In immunodeficient mice bearing HUT-102 xenotransplants, AUY922 markedly retarded tumor growth, compared with the control group. Apoptosis was evident in hematoxylin and eosin stained‑ and terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling-labeled tissue sections from AUY922‑treated mice. In addition, AUY922 significantly reduced the serum levels of the surrogate tumor markers soluble interleukin‑2 receptor and soluble cluster of differentiation 30. Overall, the present results demonstrate that AUY922 has potent anti‑ATLL activity, thus providing a rationale for continuing the clinical development of HSP90 inhibitors in clinical trials for the treatment of patients with ATLL.

View Figures

View References

1	Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD and Gallo RC: Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA. 77:7415–7419. 1980. View Article : Google Scholar : PubMed/NCBI
2	Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI, Shirakawa S and Miyoshi I: Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA. 78:6476–6480. 1981. View Article : Google Scholar : PubMed/NCBI
3	Yoshida M, Miyoshi I and Hinuma Y: Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA. 79:2031–2035. 1982. View Article : Google Scholar : PubMed/NCBI
4	Bazarbachi A, Suarez F, Fields P and Hermine O: How I treat adult T-cell leukemia/lymphoma. Blood. 118:1736–1745. 2011. View Article : Google Scholar : PubMed/NCBI
5	Ishitsuka K and Tamura K: Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol. 15:e517–e526. 2014. View Article : Google Scholar : PubMed/NCBI
6	Banerji U: Heat shock protein 90 as a drug target: Some like it hot. Clin Cancer Res. 15:9–14. 2009. View Article : Google Scholar : PubMed/NCBI
7	Hong DS, Banerji U, Tavana B, George GC, Aaron J and Kurzrock R: Targeting the molecular chaperone heat shock protein 90 (HSP90): Lessons learned and future directions. Cancer Treat Rev. 39:375–387. 2013. View Article : Google Scholar : PubMed/NCBI
8	Yan P, Qing G, Qu Z, Wu CC, Rabson A and Xiao G: Targeting autophagic regulation of NFkappaB in HTLV-I transformed cells by geldanamycin: Implications for therapeutic interventions. Autophagy. 3:600–603. 2007. View Article : Google Scholar : PubMed/NCBI
9	Kurashina R, Ohyashiki JH, Kobayashi C, Hamamura R, Zhang Y, Hirano T and Ohyashiki K: Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells. Cancer Lett. 284:62–70. 2009. View Article : Google Scholar : PubMed/NCBI
10	Ikebe E, Kawaguchi A, Tezuka K, et al: Oral administration of an HSP90 inhibitor, 17-DMAG, intervenes tumor-cell infiltration into multiple organs and improves survival period for ATL model mice. Blood Cancer J. 3:e1322013. View Article : Google Scholar : PubMed/NCBI
11	Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, et al: Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol. 23:4152–4161. 2005. View Article : Google Scholar : PubMed/NCBI
12	Ramanathan RK, Egorin MJ, Erlichman C, et al: Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J Clin Oncol. 28:1520–1526. 2010. View Article : Google Scholar : PubMed/NCBI
13	Kelland LR, Sharp SY, Rogers PM, Myers TG and Workman P: DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst. 91:1940–1949. 1999. View Article : Google Scholar : PubMed/NCBI
14	Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, Patterson L, de Haven Brandon A, Gowan S, Boxall F, et al: NVP-AUY922: A novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 68:2850–2860. 2008. View Article : Google Scholar : PubMed/NCBI
15	Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J, Quadt C, Buckler A, Cozens R, Drysdale MJ, et al: NVP-AUY922: A small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res. 10:R332008. View Article : Google Scholar : PubMed/NCBI
16	Kamihira S, Atogami S, Sohda H, Momita S, Yamada Y and Tomonaga M: Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia. Cancer. 73:2753–2758. 1994. View Article : Google Scholar : PubMed/NCBI
17	Nishioka C, Takemoto S, Kataoka S, Yamanaka S, Moriki T, Shoda M, Watanabe T and Taguchi H: Serum level of soluble CD30 correlates with the aggressiveness of adult T-cell leukemia/lymphoma. Cancer Sci. 96:810–815. 2005. View Article : Google Scholar : PubMed/NCBI
18	Xu W and Neckers L: Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res. 13:1625–1629. 2007. View Article : Google Scholar : PubMed/NCBI
19	Taniguchi H, Hasegawa H, Sasaki D, Ando K, Sawayama Y, Imanishi D, Taguchi J, Imaizumi Y, Hata T, Tsukasaki K, et al: Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia-lymphoma cells. Cancer Sci. 105:1601–1608. 2014. View Article : Google Scholar : PubMed/NCBI
20	Sessa C, Shapiro GI, Bhalla KN, Britten C, Jacks KS, Mita M, Papadimitrakopoulou V, Pluard T, Samuel TA, Akimov M, et al: First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res. 19:3671–3680. 2013. View Article : Google Scholar : PubMed/NCBI
21	Doi T, Onozawa Y, Fuse N, Yoshino T, Yamazaki K, Watanabe J, Akimov M, Robson M, Boku N and Ohtsu A: Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 74:629–636. 2014. View Article : Google Scholar : PubMed/NCBI